Novo Nordisk is preparing for what may be the most consequential internal reorganization in its modern history, as the Danish pharmaceutical giant faces a narrowing window to protect the revenue engine that turned it into Europe’s most valuable company.
A Patent Clock That Cannot Be Stopped
The core issue is semaglutide – the active ingredient in both Ozempic and Wegovy. Novo Nordisk holds patents on various formulations and delivery mechanisms, but the underlying molecule’s base patent protection will not hold indefinitely, and the company knows it. Generic manufacturers and biosimilar developers across Asia, Europe, and North America have already begun filing challenges and building production capacity. The legal machinery is already in motion.
What makes this moment especially sharp is timing. Ozempic and Wegovy together account for a disproportionate share of the company’s total revenue – a concentration that worked brilliantly during the GLP-1 boom but now creates real exposure. A broad patent erosion, even a partial one affecting select markets, would not just reduce earnings. It would force a fundamental rethink of how the company allocates capital, staffs its commercial operations, and prioritizes its pipeline.
Novo Nordisk’s leadership has signaled awareness of this pressure. The company has already posted job cuts at certain manufacturing and administrative levels, with reports indicating several hundred positions being reviewed or eliminated in Denmark and at its U.S. operations. These are not routine efficiency trims. They suggest a company stress-testing its cost structure against multiple revenue scenarios, including ones where semaglutide faces meaningful pricing pressure within five years.
The restructuring conversations reportedly extend into commercial strategy, research prioritization, and how aggressively to defend market share versus investing in next-generation molecules. Novo Nordisk has CagriSema – a combination of semaglutide and cagrilintide – in late-stage development, along with oral GLP-1 candidates. The pipeline is real. The question is whether it can generate the kind of blockbuster returns that semaglutide has delivered before competition floods the injectable weight-loss market.
The Competitive Pressure Building Around Them
Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has already demonstrated that Novo Nordisk does not have the GLP-1 space to itself. Lilly’s drug targets two receptors rather than one and has shown strong efficacy results. Novo Nordisk’s internal modeling must account for a world where it competes not just with biosimilar versions of its own drug, but with structurally different molecules from well-capitalized rivals.
Compounding this is the compounding pharmacy issue in the United States. During the period when branded semaglutide faced supply shortages, the FDA permitted compounding pharmacies to produce versions of the drug at significantly lower cost. That window officially closed, but the episode demonstrated how quickly patients and prescribers can adapt when price differentials are large enough. It also showed that demand for these drugs is real and durable – which is a double-edged signal for Novo Nordisk. High demand attracts competition, and competition eventually kills premium pricing.
The company is also navigating political pressure on drug pricing in the United States, its largest single market. GLP-1 drugs became a flash point in the broader debate about pharmaceutical costs, and Novo Nordisk has faced direct congressional scrutiny over the gap between U.S. prices and what patients pay in Europe or Canada. Any legislative movement toward direct Medicare negotiation on these drugs – which is already underway for other categories – could cut into margins faster than patent expiry alone.
On the manufacturing side, Novo Nordisk has spent aggressively to build out fill-and-finish capacity after being caught short during the initial Ozempic demand surge. That investment was necessary, but it also locks in significant fixed cost. If revenue per unit falls due to competition or pricing pressure, the company will be carrying infrastructure scaled for a higher-margin world. That is the kind of structural mismatch that forces difficult decisions about workforce size and operational footprint.
The restructuring is also being watched by investors who drove Novo Nordisk’s market capitalization to extraordinary heights on the strength of GLP-1 momentum. The stock has already pulled back meaningfully from its 2024 peak, partly on disappointing trial data for CagriSema’s weight loss outcomes – which came in below expectations in one key readout. That miss rattled confidence in the company’s ability to sustain growth through a next-generation product alone, and it is part of why the internal cost and strategy review has taken on added urgency.
What the Restructuring Actually Signals
A corporate restructuring at this scale, when a company’s core product still generates strong revenue, is not a crisis response. It is a hedge. Novo Nordisk is not waiting for patent cliffs to arrive before adjusting its operating model – it is trying to reshape its cost base and strategic focus while it still has the cash flow to do so on its own terms. That approach is disciplined, but it is also an admission that the semaglutide era as currently structured has a ceiling, and the company is now building for what comes after.
The harder question is whether the next generation of GLP-1 drugs can be developed, approved, and commercialized before the generic pressure on existing products becomes severe enough to affect R&D budgets. Novo Nordisk is not a small company – its resources and institutional knowledge in metabolic disease are formidable. But the gap between a promising pipeline molecule and a revenue-generating blockbuster is where pharmaceutical strategy lives or dies, and right now that gap is exactly where Novo Nordisk’s future is being written.
